Am J Health-Syst Pharm. 1999; 56:985-9 dministering cancer chemotherapy by continuous intravenous infusion (CIVI) has several potential advantages over administration by short intravenous infusions 1 and has been facilitated by the development of portable infusion pumps.
Hodgkin's lymphoma. In that study, etoposide 50 mg/ m 2 /day, vincristine sulfate 0.4 mg/m 2 /day, and doxorubicin hydrochloride 10 mg/m 2 /day were administered as a CIVI for four days. The doxorubicin and vincristine doses were provided in the same container 4 and delivered by one portable infusion pump through one lumen of a central venous catheter (CVC). In the absence of compatibility data, the etoposide dose was delivered by a second portable infusion pump through a different lumen of the CVC. Evidence that these three drugs are compatible and stable under conditions that simulate actual-use concentrations and conditions would facilitate drug delivery for the EPOCH regimen.
The purpose of this study was to determine the physical compatibility and chemical stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide-at concentrations that would simulate those used in the clinical study-when mixed in 0.9% sodium chloride injection and stored in polyolefin-lined infusion bags in the light or in the dark at 23-25 or 31-33 °C for up to 96 hours.
Methods. Preparation of admixtures.
Five sets of admixtures containing vincristine, doxorubicin, and etoposide were prepared in quadruplicate at concentrations appropriate for patients with body surface areas (BSAs) of 1.25, 1.75, and 2.5 m 2 who would receive this portion of the EPOCH regimen as 500-mL admixtures, lasting 24 or 48 hours apiece. These admixtures contained vincristine sulfate, a doxorubicin hydrochloride, ). The drugs were added to polyolefin-lined i.v. bags containing 250 mL of 0.9% Sodium Chloride Injection, USP d ; 250 mL was selected as the admixture volume to conserve drugs. The 20 admixtures were stored at 23-25 °C for up to 96 hours; 2 admixtures from each set were exposed to fluorescent light, and the rest were protected from light. The admixtures were prepared with aseptic technique in a biological safety cabinet.
Another two admixtures were prepared in concentrations appropriate for patients with a BSA of 2.0 m 2 who would receive the drugs as 500-mL admixtures lasting 24 hours apiece. These admixtures, containing vincristine sulfate 1.6 µg/mL, doxorubicin hydrochloride 40.0 µg/mL, and etoposide 200.0 µg/mL, were prepared in the same manner as the other admixtures but were stored at 31-33 °C for 72 hours and protected from light. The higher storage temperature was selected to simulate environmental conditions other than a controlled-temperature laboratory.
Visual analysis and pH measurement. phosphate, pH 3.5) and 90% acetonitrile in water were used. All reagents were of HPLC grade and were filtered and degassed before use. The injection volume was 20 µL, and the flow rate was 1 mL/min. The spectrophotometer was programmed to detect at 287 nm for 0 to 12.50 minutes and at 221 nm for 11.5 to 18.0 minutes. Changing the absorption wavelength during the chromatographic run from 287 to 221 nm made it possible to optimize the peak height of all three drugs, because doxorubicin, etoposide, and vincristine have absorbance maxima at 290 nm, 5 283 nm, 6 and 221 nm, 7 respectively. All samples were analyzed at room temperature. Under these conditions, the retention times for doxorubicin hydrochloride, etoposide, and vincristine sulfate were 9.1, 10.2, and 15.0 minutes, respectively ( Figure 1 ). Five-point standard curves were constructed by using USP reference standards of vincristine sulfate k (0.5-4 µg/mL), doxorubicin hydrochloride l (13-100 µg/mL), and etoposide m (60-500 µg/mL). The correlation coefficients were 0.99, 0.999, and 0.996, respectively. The within-day variations for vincristine, doxorubicin, and etoposide concentrations were 1.40%, 0.78%, and 0.7%, respectively. After every 10 samples, an external standard (a sample of an admixture of vincristine, doxorubicin, and etoposide) was assayed to validate the reproducibility of the assay. The between-day variations were 2.7%, 1.8%, and 2.0% for vincristine, doxorubicin, and etoposide, respectively. The concentration of each drug in the admixture was determined by comparing the peak area of drug with the respective standard curve. Benzyl alcohol, methylparaben, and propylparaben were identified by comparison to standard. None of these additives interfered with the peaks of interest. No other excipients were detected.
To validate the stability-indicating capability of the assay, each of the drugs was exposed to 0.1 N hydrochloric acid and 0.1 N sodium hydroxide at room temperature. The concentrations of the drugs in the decomposition experiments were the same as in one of the admixtures (vincristine sulfate 1.4 µg/mL, doxorubicin hydrochloride 35.0 µg/mL, and etoposide 175.0 µg/mL). Portions of the six solutions were then injected onto the chromatograph to detect the presence of interfering peaks. The degradation peaks of doxorubicin in alkaline solution had a retention time (relative to the doxorubicin peak) of 0.49 and 0.72. Vincristine degraded in alkaline solution to give degradation products with retention times (relative to the vincristine peak) of 0.36 and 0.42. Etoposide in 0.1 N sodium hydroxide yielded a degradation product that had a retention time (relative to the etoposide peak) of 0.52. The peak area of vincristine decreased with time in the acidic solution, but no peak for a degradation product was observed in the chromatogram. Etoposide reacted in acidic solution to form a product with a relative retention time of 0.33. Doxorubicin reacted in acidic solution to yield a product with a relative retention time of 1.5. To ascertain that the peak for this product of doxorubicin degradation did not interfere with the peak for intact vincristine, a portion of vincristine was added to the degraded doxorubicin, and the mixture was analyzed by HPLC, which revealed two distinct peaks with retention times (relative to the doxorubicin peak) of 1.5 and 1.7, the latter belonging to vincristine. Data analysis. Compatibility was defined as no color change or precipitation in an admixture. The drugs were considered stable in an admixture if >90% of the initial concentrations of the drugs were present.
Results. At 23-25 °C, there was no color change or precipitate in the admixtures, provided that the concentration of etoposide was <250 µg/mL. At etoposide concentrations of ≥250 µg/mL, there was a precipitate in the admixtures, regardless of lighting conditions. Admixtures containing etoposide 250, 350, and 500 µg/mL precipitated in 72, 36, and 12 hours, respectively. The precipitate was not observed in the admixtures stored at 31-33 °C in the dark for 72 hours (the etoposide concentration was 200 µg/mL). To confirm that etoposide was the precipitate, the solutions containing precipitate were filtered, the precipitate was dissolved, and the resulting solution was injected into the HPLC system. The pH of the admixtures under the different conditions ranged from 3.4 to 3.8.
At 23-25 °C, vincristine sulfate, doxorubicin hydrochloride, and etoposide retained >92% of their initial concentrations in the admixtures without precipitates (Table 1 ). Drugs exposed to slightly elevated temperatures (31-33 °C) retained >94% of their initial concentrations for up to 72 hours after preparation (Table 2) .
Conclusion. In the combinations of vincristine sulfate, doxorubicin hydrochloride, and etoposide studied, all drugs were compatible and stable for up to 72 hours in 0.9% sodium chloride injection in polyolefin-lined i.v. bags at 23-25 °C, provided that the concentration of etoposide was <250 µg/mL. Vincristine sulfate 1.6 µg/mL, doxorubicin hydrochloride 40 µg/mL, and etoposide 200 µg/mL were compatible and stable for up to 72 hours in the dark at 31-33 °C. 
